Evidence map›Paper›PMID 40478147›Full record

ArticleOpenNano2023

Carbon-based nanomaterials against SARS-CoV-2: Therapeutic and diagnostic applications.

Sepideh Ahmadi, Majid Ebrahimi Warkiani, Mohammad Rabiee, Siavash Iravani, Navid Rabiee

Abstract read
In one paragraph

Article in OpenNano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sepideh AhmadiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
Mohammad RabieeBiomaterial Group, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
Siavash IravaniFaculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Navid RabieeSchool of Engineering, Macquarie University, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, which was first spread in China in 2019 and consequently spread worldwide, is caused by the SARS-CoV-2. Today, various carbon-based nanomaterials such as graphene, graphene oxide, carbon dots, and carbon nanotubes have been explored for the specific detection and targeted inhibition/inactivation of SARS-CoV-2 due to their great surface chemical structures, easy to-functionalization, biocompatibility, and low toxicity. According to exclusive inherent properties, carbon-based nanomaterials are promising candidates for targeted antiviral drug delivery and the inhibitory effects against pathogenic viruses based on photothermal effects or reactive oxygen species (ROS) formation.  These high-stability nanomaterials exhibited unique physicochemical properties, providing efficient nanoplatforms for optical and electrochemical sensing and diagnostic applications with high sensitivity and selectivity. Up to now, these materials have been used for the fabrication of diagnostic kits, different types of personal protective equipment (PPE) such as anti-viral masks, vaccines, self-cleaning surfaces, and other subjects. This review article explores the most recent developments in carbon-based nanomaterials' diagnostic and therapeutic potential towards SARS-CoV-2 detection and inhibition, different mechanisms, challenges and benefits of the carbon-based nanomaterials.

Indexed as

Carbon-based nanomaterialsDiagnosticsNanosensorsSARS-CoV-2Sensing applicationsTherapeutics

Identifiers

PMID40478147
PMCPMC9937779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.